Clinical Trial and Research Programs
 

Our clinical research and trial program was started in 1998, over the frustration of our advanced prostate cancer patients having to travel to UCLA for special treatment protocols.  Since then, we have acquired both a great deal of experience and the reputation as a center of excellence in clinical research.  We have been selected to participate in multiple trials sponsored by National Cancer Institute or major pharmaceutical and biotech companies.  We have also agreed to be part of UCLA’s Community Prostate Cancer Group.


IV Chemo Therapy Room


Sub 0 Freezer

The following protocols are ongoing and open for enrollment at this time(01/2008): 
 

             ---------------------- PROSTATE CANCER ----------------------

 

Study Name

  Pharmaceutical
Company/Sponsor
 

Prostate Cancer, Rising PSA after Radical Prostatectomy
– Eligard + Taxotere/ Phase III

Sanofi-Aventis (3503)
 

Hormone Refractory Cancer of the prostate (early)  Casodex
+/- Avodart / Phase III

GlaxoSmithKline

                   ---------------------- ADVANCED CANCER OF PROSTATE ----------------------

 

 Study Name

  Pharmaceutical
Company/Sponsor
 

Hormone Refractory Cancer of Prostate – Chemotherapy naïve
– Taxotere + vaccine Phase III 

Cell Genesys
     
 

Hormone Refractory Cancer of Prostate – Chemotherapy naïve
– Taxotere + monoclonal antibody – Phase II

Centocor
     
 

Hormone Refractory Cancer of Prostate – Chemotherapy naïve
or previously Taxotere patients – Phase II

Infinity Pharmaceutical
     
 

Hormone Refractory Cancer of Prostate – Previously Taxotere
resistant patients – Phase III

Sanofi-Aventis
     
 

Hormone Refractory Cancer of Prostate – Chemotherapy naïve
or previously Taxotere patients – Phase II

Active Biotech


             ---------------------- OVERACTIVE BLADDER ----------------------

 

 Study Name

  Pharmaceutical
Company/Sponsor
 

Overactive Bladder – Phase II

Dainippon Sumitomo Pharma
 

Overactive Bladder – Phase IV

Astellas
 

Overactive Bladder with BPH (benign prostatic hypertrophy) – Phase IV

Astellas
 

Overactive Bladder with BPH (benign prostatic hypertrophy)

Pfizer


             ---------------------- BLADDER CANCER ----------------------

 

 Study Name

  Pharmaceutical
Company/Sponsor
 

Locally advanced/ metastatic bladder cancer. Phase III

Sanofi Aventis

            

The following protocols are ongoing, however closed for enrollment: (updated 1/2008)
 

             ---------------------- PROSTATE CANCER ----------------------

 

 Study Name

  Pharmaceutical
Company/Sponsor
 

Prostate cancer with Hot Flashes

Duramed
 

Prostate Cancer

GlaxoSmithKline
 

Advanced Prostate Cancer

Sanofi Aventis

 
 

Metastatic Hormone refractory prostate cancer Phase I

Centocor
 

Metastatic hormone refractory prostate cancer without pain

Cell Genesys


                   ---------------------- PROSTATE CANCER WITH BONE LOSS ----------------------

 

 Study Name

  Pharmaceutical
Company/Sponsor
  Prostate Cancer with bone loss prevention GTX
  Prostate Cancer with bone loss prevention. Amgen


                   ---------------------- HIGH RISK FOR PROSTATE CANCER ----------------------

 

 Study Name

  Pharmaceutical
Company/Sponsor
  Prostate Cancer prevention GlaxoSmithKline
  High Grade PIN GTX

 

In the last 7 years, we have conducted over 150 Phase I, II, III, and IV trials.  SBURC (San Bernardino Urological Research Center) is one of the busiest urology research centers in Southern California.  We have conducted multiple trials in the area of:

1. Prostate Cancer: multiple LHRH agonists and antagonist including Eligard.
2. Hormone Refractory Prostate Cancer: including both bioactive molecules and IV chemotherapy.
      SBURC is one of the top research sites globally in protocols with IV infusion therapies.
3. Prostate Cancer Prevention
4. Bladder Cancer & Bladder Cancer Prevention
5. Overactive Bladder: Multiple protocols with Detrol LA, Ditropan XL, Medicare(Yamanouchi),
      as well as protocols with Kyowa, Schwartz and Sepracor
6. Erectile Dysfunction: Vardenafil
7. Urinary Tract Infection: Levaquin, Cirpo XR
8. Stress Incontinence
9. Interstitial Cystitis
10. Chronic Pelvic Pain Syndrome
11. BPH
12. Testosterone Replacement

Our office has played a pivotal role in the development for Eligard (FDA approval 2002), Levaquin (FDA approval 2002), Vardenafil (submitted for NDA 2002), and Vesicare (submitted for NDA 2003), and other familiar names such as Detrol, Ditropan XL, and etc.                                        

Please call our Research Coordinator, Charity Hernandez if you have any questions or if you would like to participate in the trials @ 909-882-2973. Some of the studies do allow for patient compensations in addition to medication and medical care. Through these trial programs, we are able to deliver the most up to date urological care. Our patients have access to medications and treatment protocols that would otherwise be unavailable to them for years to come.